New drug targets Hard-to-Treat cancers with PIK3CA mutation
NCT ID NCT07383506
First seen Feb 03, 2026 · Last updated Jun 16, 2026 · Updated 18 times
Summary
This early-phase study tests an experimental drug called CGT6297 in about 90 adults whose advanced solid tumors (including certain breast and endometrial cancers) have a specific genetic change called PIK3CA. The main goals are to find a safe dose and see if the drug can shrink or control the tumors. Participants will receive the drug and be closely monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Austin
RECRUITINGAustin, Texas, 78758, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.